AstraZeneca PLC (AZN) Q2 2026 Earnings Call Highlights: Strong Oncology and Rare Disease Growth
GuruFocus News
Tue, July 28, 2026 at 12:30 AM GMT+5:30
5 min read
- AZN
+0.22%
This article first appeared on GuruFocus
Total Revenue Growth: 6% increase in the first half of 2026
Product Revenue Growth: 6% increase in the first half of 2026
Alliance Revenue Growth: 29% increase, driven by higher profit shares from partnered medicines
Core Gross Margin: 83% in the first half of 2026
Core EPS Growth: 11% increase in the first half of 2026
Core R&D Expense: Increased by 6%, representing 23% of total revenue
Core SG&A Expense: Increased by 6% in the first half of 2026
Other Operating Income: $341 million in the first six months
Capital Expenditure: $1.5 billion in the first half of 2026
Deal-related Payments: Totaled $3.3 billion, including a $1.2 billion upfront payment for CSBC collaboration
Net Debt Increase: Around $3.5 billion in the first half of 2026
Oncology Revenue Growth: 15% increase to $14.1 billion in the first half of 2026
Biopharmaceuticals Revenue Decline: 5% decrease to $11.2 billion in the first half of 2026
Rare Disease Revenue Growth: 11% increase to $4.9 billion in the first half of 2026
Warning! GuruFocus has detected 4 Warning Signs with BOM:533080
Is AZN fairly valued? Test your thesis with our free DCF calculator
For the complete transcript of the earnings call, please refer to the full earnings call transcript
Positive Points
AstraZeneca PLC (NYSE:AZN) reported a 6% increase in total revenue for the first half of 2026, with product revenue also growing by 6%
The company achieved strong growth in core EPS, increasing by 11%, demonstrating robust financial performance
AstraZeneca PLC (NYSE:AZN) announced positive results from six key Phase III programs, including three new molecular entities, and secured 30 major market approvals
The oncology and rare disease segments delivered strong double-digit growth, with notable revenue increases in the US and Europe
AstraZeneca PLC (NYSE:AZN) continues to invest in its pipeline and commercial capabilities, with a focus on innovative medicines and long-term growth opportunities
Negative Points
Growth in China was impacted by continued effects from volume-based procurement, affecting overall revenue growth
The results of the cardio-TTR transform trial were disappointing, highlighting the inherent risks in transformative science
AstraZeneca PLC (NYSE:AZN) faces challenges from loss of exclusivity for key products like Fasiga and Brilinta, impacting revenue
The company anticipates a lower gross margin in the second half of the year due to seasonal demand patterns for lower margin medicines
Net debt increased by around $3.5 billion in the first half, primarily due to dividend payments and deal-related expenses
